HC Wainwright & Co. Reiterates Buy on Reneo Pharmaceuticals, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Reneo Pharmaceuticals (NASDAQ:RPHM) and maintained a $30 price target on the company's stock.
November 14, 2023 | 11:29 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Reneo Pharmaceuticals with a $30 price target, potentially influencing investor confidence and the stock's performance.
The reiteration of a Buy rating and maintenance of a $30 price target by a reputable analyst could lead to increased investor confidence in Reneo Pharmaceuticals, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100